Metrics to compare | FLUIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFLUICPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.6x | −3.1x | −0.5x | |
PEG Ratio | - | 0.01 | 0.00 | |
Price / Book | 2.7x | 2.2x | 2.6x | |
Price / LTM Sales | 1.9x | 4.4x | 3.1x | |
Upside (Analyst Target) | - | 0.0% | 55.1% | |
Fair Value Upside | Unlock | 16.9% | 7.2% | Unlock |
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet. Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.